Clinical Trial Update: Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) [Phase 3]

View source ↗

Summary

Phase 3 trial KEYNOTE-826 evaluating pembrolizumab plus chemotherapy vs placebo plus chemotherapy in first-line cervical cancer; results demonstrating efficacy …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Cervical Cancer | Phase 3 | Status: COMPLETED | Results posted: 2023-10-12